PDL Biopharma (Nasdaq: PDLI ) is trading near a 52-week high, and its share price has appreciated more than 30% year to date. This company's revenue comes from licensing its valuable intellectual property to biotech and pharma companies including Roche, Biogen Idec, and Eli Lilly. PDL Biopharma certainly has a unique business model, but it's perhaps known best by investors for its whopping 7.3% dividend yield.
In the following video, health care analyst Max Macaluso and bureau chief Brenton Flynn discuss both the opportunities and risks that face this stock.
If PDL Biopharma's attractive dividend has piqued your interest, The Motley Fool has compiled a special free report outlining our top nine dividend-paying stocks. You can access your copy of "Secure Your Future With 9 Rock-Solid Dividend Stocks" for free. Just click here to discover the winners we've picked.